NASDAQ: SGPSpyglass Pharma Inc Stock
$22.61-2.59 (-10.28%)
Updated Mar 27, 2026
SpyGlass Pharma shares are trading... find out Why SGP Price Moved with a free WallStreetZen account
Why Price MovedSGP Price
$22.61
Fair Value Price
N/A
Market Cap
$755.77M
52 Week Low
$20.16
52 Week High
$32.44
P/E
-1.26x
P/B
-7.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.1
Operating Cash Flow
-$33M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SGP Overview
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SGP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SGP
Ranked#83 of 99
Ranked#83 of 99
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.94 | A | |
| $9.25 | A | |
| $26.34 | A |
Be the first to know about important SGP news, forecast changes, insider trades & much more!
SGP News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SGP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SGP is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SGP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SGP due diligence checks available for Premium users.
Valuation
SGP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.26x
Industry
24.92x
Market
30.7x
SGP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-7.65x
Industry
3.3x
SGP's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.6M
Profit Margin
0%
SGP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$115.9M
Liabilities
$10.2M
Debt to equity
-0.1
SGP's short-term assets ($108.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGP's short-term assets ($108.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SGP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.3M
Investing
$574.7k
Financing
-$889.6k
SGP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SGP vs Medical Device Stocks
Spyglass Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.